Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.

Matthews ML.

J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):e1-7. doi: 10.1331/JAPhA.2013.12025. Review.

PMID:
23636166
2.

Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.

Stanos S.

Phys Sportsmed. 2012 Nov;40(4):12-20. doi: 10.3810/psm.2012.11.1975. Review.

PMID:
23306411
3.

Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.

Gudin J.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):136-43. doi: 10.3109/15360288.2012.679724.

PMID:
22764852
4.

Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.

Nicholson SC, Evanyo K, Salinas GD, Roepke N, Burton BS, Susalka D.

J Opioid Manag. 2012 Jul-Aug;8(4):212-6. doi: 10.5055/jom.2012.0118.

PMID:
22941848
5.

ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.

Cepeda MS, Coplan PM, Kopper NW, Maziere JY, Wedin GP, Wallace LE.

Pain Med. 2017 Jan 1;18(1):78-85. doi: 10.1093/pm/pnw129.

6.

Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.

Slevin KA, Ashburn MA.

J Opioid Manag. 2011 Mar-Apr;7(2):109-15.

PMID:
21561034
7.
8.
9.

Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.

Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):123-6. doi: 10.3109/15360288.2012.677946.

PMID:
22764848
10.

Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.

Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.

PMID:
26469747
11.

SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.

Alford DP, Zisblatt L, Ng P, Hayes SM, Peloquin S, Hardesty I, White JL.

Pain Med. 2016 Jan;17(1):52-63.

12.

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.

Mercadante S, Craig D, Giarratano A.

Drugs. 2012 Dec 24;72(18):2327-32. doi: 10.2165/11642230-000000000-00000. Review.

PMID:
23116252
13.

The Food and Drug Administration risk evaluation and mitigation strategy.

Craig DS.

J Pain Palliat Care Pharmacother. 2010 Jun;24(2):145-8. doi: 10.3109/15360281003713834.

PMID:
20504137
14.

Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).

Nelson LS, Perrone J.

JAMA. 2012 Aug 1;308(5):457-8. doi: 10.1001/jama.2012.8165. No abstract available.

PMID:
22851109
15.

APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.

American Pharmacists Association, Bough M.

J Am Pharm Assoc (2003). 2011 May-Jun;51(3):340-58. doi: 10.1331/JAPhA.2011.11519.

PMID:
21555285
16.

ER/LA opioid REMS and accredited education: Survey results provide insight into clinical roles, educational needs, and learner preferences.

Kear C, McKeithen T, Robertson S.

Subst Abus. 2017 Apr-Jun;38(2):145-149. doi: 10.1080/08897077.2017.1303422.

PMID:
28418777
17.

Implementation of an opioid management initiative by a state Medicaid program.

Garcia MM, Angelini MC, Thomas T, Lenz K, Jeffrey P.

J Manag Care Spec Pharm. 2014 May;20(5):447-54.

18.

Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?

Brooks MJ.

Mayo Clin Proc. 2014 Dec;89(12):1673-84. doi: 10.1016/j.mayocp.2014.09.003. Epub 2014 Nov 4.

19.

FDA opioid safety plan promotes patient, physician education to prevent abuse.

Kuehn BM.

JAMA. 2010 Aug 25;304(8):845. doi: 10.1001/jama.2010.1200. No abstract available.

PMID:
20736462
20.

Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.

Shane R.

Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S6-S12. doi: 10.2146/ajhp090461.

PMID:
19966079

Supplemental Content

Support Center